chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dehydration, Fatigue, Headache, Nausea
Clinical narrative: Fever; Chills; Nausea; Tiredness; Body-aches/Soreness; Small red rash near injection site; Persistent Headache; Dehydration; This is a spontaneous report received from a contactable consumer, the patient. A 31-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO175) via an unspecified route of administration in the left arm on 22Apr2021 at 10:30 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history included VITMAIN D deficiency and allergy to PENICILLIN. It was unknown if the patient was pregnant. Concomitant medications included VITMAIN D 50000 MG. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO150) via an unspecified route of administration in the left arm on 01Apr2021 at 16:30 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. On 23Apr2021 at 21:00, the patient experienced fever, chills, nausea, tiredness, body-aches, soreness, small red rash near injection site, persistent headache, and dehydration. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills, nausea, tiredness, body-aches, soreness, small red rash near injection site, persistent headache, and dehydration was resolved with sequelae (also reported as recovered with lasting effects) on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Vaccination site rash
Clinical narrative: Fever; Chills; Nausea; Tiredness; Body-aches/Soreness; Small red rash near injection site; Persistent Headache; Dehydration; This is a spontaneous report received from a contactable consumer, the patient. A 31-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO175) via an unspecified route of administration in the left arm on 22Apr2021 at 10:30 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history included VITMAIN D deficiency and allergy to PENICILLIN. It was unknown if the patient was pregnant. Concomitant medications included VITMAIN D 50000 MG. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO150) via an unspecified route of administration in the left arm on 01Apr2021 at 16:30 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. On 23Apr2021 at 21:00, the patient experienced fever, chills, nausea, tiredness, body-aches, soreness, small red rash near injection site, persistent headache, and dehydration. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills, nausea, tiredness, body-aches, soreness, small red rash near injection site, persistent headache, and dehydration was resolved with sequelae (also reported as recovered with lasting effects) on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Fatigue, Headache, Joint range of motion decreased
Clinical narrative: I got a mild skin rash on my chest, but it wasn't really itchy; my arm swelled a little and was very tender; Chills; headache; body aches/pains; extreme fatigue; had limited range of motion; shoulder and arm pain; shoulder and arm pain; shooting pain; This is a spontaneous report from a contactable consumer or other non hcp.   A 47-years-old female non Pregnant patient received bnt162b2 (BNT162B2 PFIZER-BIONTECH COVID-19 MRNA VACCINE; Solution for injection (Batch/Lot Number: ER8731), dose 2 via an unspecified route of administration, administered in Arm Left on 10Apr2021 11:30 as 2nd dose, single for covid-19 immunisation. Medical history included ongoing Multiple sclerosis. Concomitant medication(s) included natalizumab (TYSABRI); melatonin (MELATONIN); zolpidem tartrate (AMBIEN. The patient previously took bnt162b2 for covid-19 immunisation, tetracycline. The patient did not receive any other vaccine in four weeks. Prior to vaccination patient was not diagnosed with COVID. Post vaccination patient did not test for COVID It was Reported that, on 11 Apr2021 07:00 evening after she received the vaccine, my arm swelled a little and was very tender.The next morning, woke up and felt minor chills, headache, body aches/pains and extreme fatigue. This continued for two days. Two days after the vaccine got a mild skin rash on my chest, but it wasn't really itchy.It went away less than 24 hours later.  By the third day after was only fatigued. Day 4 or 5 I was back to normal, had limited range of motion, shoulder and arm pain, shooting pain when I move it in certain directions. The outcome of the event was not recovered. The patient underwent lab tests and procedures which included sars-cov-1 test negative: negative on 14Apr2021. Therapeutic measures were taken as a result of Physical Therapy, had limited range of motion (joint range of motion decreased), shoulder and arm pain (arthralgia), shoulder and arm pain (pain in extremity), shooting pain (pain).  Follow-Up (08Jul2021): Follow-up attempts are completed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pain in extremity, Peripheral swelling, Rash, SARS-CoV-1 test negative
Clinical narrative: I got a mild skin rash on my chest, but it wasn't really itchy; my arm swelled a little and was very tender; Chills; headache; body aches/pains; extreme fatigue; had limited range of motion; shoulder and arm pain; shoulder and arm pain; shooting pain; This is a spontaneous report from a contactable consumer or other non hcp.   A 47-years-old female non Pregnant patient received bnt162b2 (BNT162B2 PFIZER-BIONTECH COVID-19 MRNA VACCINE; Solution for injection (Batch/Lot Number: ER8731), dose 2 via an unspecified route of administration, administered in Arm Left on 10Apr2021 11:30 as 2nd dose, single for covid-19 immunisation. Medical history included ongoing Multiple sclerosis. Concomitant medication(s) included natalizumab (TYSABRI); melatonin (MELATONIN); zolpidem tartrate (AMBIEN. The patient previously took bnt162b2 for covid-19 immunisation, tetracycline. The patient did not receive any other vaccine in four weeks. Prior to vaccination patient was not diagnosed with COVID. Post vaccination patient did not test for COVID It was Reported that, on 11 Apr2021 07:00 evening after she received the vaccine, my arm swelled a little and was very tender.The next morning, woke up and felt minor chills, headache, body aches/pains and extreme fatigue. This continued for two days. Two days after the vaccine got a mild skin rash on my chest, but it wasn't really itchy.It went away less than 24 hours later.  By the third day after was only fatigued. Day 4 or 5 I was back to normal, had limited range of motion, shoulder and arm pain, shooting pain when I move it in certain directions. The outcome of the event was not recovered. The patient underwent lab tests and procedures which included sars-cov-1 test negative: negative on 14Apr2021. Therapeutic measures were taken as a result of Physical Therapy, had limited range of motion (joint range of motion decreased), shoulder and arm pain (arthralgia), shoulder and arm pain (pain in extremity), shooting pain (pain).  Follow-Up (08Jul2021): Follow-up attempts are completed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Dehydration, Headache, Pain of skin
Clinical narrative: Severe chills; Fever 99.5; Severe headache; Skin hurt; Dehydration; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 23Apr2021 at 11:45 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy (sulfa type antibiotics) and penicillin allergy (PCN antibiotic). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medication was not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Apr2021 at 02:00, 14 hours after 2nd dose, the patient experienced severe chills, fever 99.5, severe headache, skin hurt and dehydration. On the same day, the patient underwent a body temperature test and the result was 99.5 (UNSPECIFIED UNITS). The events did not result in doctor or other healthcare professional office/clinic visits, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe chills, fever 99.5, severe headache, skin hurt and dehydration was recovered on 24Apr2021 at 17:00, after the duration of 15 hours.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Severe chills; Fever 99.5; Severe headache; Skin hurt; Dehydration; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 23Apr2021 at 11:45 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy (sulfa type antibiotics) and penicillin allergy (PCN antibiotic). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medication was not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Apr2021 at 02:00, 14 hours after 2nd dose, the patient experienced severe chills, fever 99.5, severe headache, skin hurt and dehydration. On the same day, the patient underwent a body temperature test and the result was 99.5 (UNSPECIFIED UNITS). The events did not result in doctor or other healthcare professional office/clinic visits, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe chills, fever 99.5, severe headache, skin hurt and dehydration was recovered on 24Apr2021 at 17:00, after the duration of 15 hours.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Disturbance in attention, Headache
Clinical narrative: Mild headache and extreme difficulty mentally focusing at 5 days and counting.; extreme difficulty mentally focusing at 5 days and counting. This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the right arm on 25Mar2021 at 11:15 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. The medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within two weeks of vaccination. The patient previously received loratadine (CLARITIN) on an unknown date and experienced allergy. On 04Apr2021 at 22:00, the patient experienced mild headache and extreme difficulty in mentally focusing at 5 days and counting. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room or department/urgent care. Therapeutic measures were not taken as a result of reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events mild headache and extreme difficulty in mentally focusing was not recovered at the time of this report. The patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 15Apr2021 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Eye pruritus, Insomnia, Nasal pruritus, Sneezing
Clinical narrative: Nose becomes very itchy; Have thousands of sneeze, uncontrollable sneezes.; Feel a little of itchy eyes; Couldn't sleep well at night because of the itchy nose; This is a spontaneous report from a non-contactable consumer, the patient. A 37-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 21Apr2021 at 09:15 at the age of 37-years-old as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. On 22Apr2021, the patient's nose became very itchy and had thousands of sneezes, uncontrollable sneezes. The patient also felt a little of itchy eyes and couldn't sleep well at night because of the itchy nose. The patient never had any allergic reaction in life before. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events nose became very itchy, thousands of sneeze uncontrollable sneezes, itchy eyes and couldn't sleep well at night because of the itchy nose was not recovered at the time of this report.   No follow-up attempts are possible, information about lot/batch number cannot be obtained. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Cough, Diarrhoea, Eye discharge, Fatigue
Clinical narrative: Period starts 5 days early; Abdominal cramping; Sneezing constantly; Dry but runny nose/ moderate runny nose/ mild runny nose; Mild cough; Dry but runny eyes/ moderate runny eyes/ mild runny eyes; Rash on hands, face, and chest; 7-10 episodes of vomiting; Moderate fatigue /extremely fatigued; Frequent diarrhea/ moderate diarrhea; Mild nausea / severe nausea /moderate nausea; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 18Apr2021 at 14:00 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history includes bipolar 1, attention deficit-hyperactivity disorder (ADHD), anxiety, post-traumatic stress disorder (PTSD), arthritis, asthma, psoriasis, COVID-19, allergic to cats and certain food colorings if ingested. Prior to vaccination, the patient was diagnosed with COVID-19. Concomitant medications included lithium carbonate (MANUFACTURER UNKNOWN), quetiapine fumarate (SEROQUEL), lisdexamfetamine mesilate (VYVANSE) and hydroxyzine (MANUFACTURER UNKNOWN); all for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to vaccination. On 19Apr2021 at 17:30, day 1, the patient experienced moderate fatigue, frequent diarrhea and mild nausea. On 20Apr2021, day 2-4, the patient experienced sneezing constantly, dry but runny eyes and nose, mild cough, extremely fatigued, rash on hands, face, and chest, frequent diarrhea, 7- 10 episodes of vomiting, severe nausea and no soreness. On 23Apr2021,day 5, the patient had abdominal cramping, moderate runny nose and eyes, sneezing, moderate nausea and frequent diarrhea. On 24Apr2021, day 6, the period started 5 days early and experienced extremely fatigued, no sneezing, mild runny eyes and nose, no nausea and moderate diarrhea. The patient did not have any swelling or soreness and reported that vaccine was painless. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events moderate fatigue, frequent diarrhea, mild nausea, sneezing constantly, dry but runny eyes and nose, mild cough, extremely fatigued, rash on hands, face, and chest, 7- 10 episodes of vomiting, severe nausea, abdominal cramping, moderate runny nose and eyes, moderate nausea and period started 5 days early was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Menstruation irregular, Nausea, Rash, Rhinorrhoea, Sneezing
Clinical narrative: Period starts 5 days early; Abdominal cramping; Sneezing constantly; Dry but runny nose/ moderate runny nose/ mild runny nose; Mild cough; Dry but runny eyes/ moderate runny eyes/ mild runny eyes; Rash on hands, face, and chest; 7-10 episodes of vomiting; Moderate fatigue /extremely fatigued; Frequent diarrhea/ moderate diarrhea; Mild nausea / severe nausea /moderate nausea; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 18Apr2021 at 14:00 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history includes bipolar 1, attention deficit-hyperactivity disorder (ADHD), anxiety, post-traumatic stress disorder (PTSD), arthritis, asthma, psoriasis, COVID-19, allergic to cats and certain food colorings if ingested. Prior to vaccination, the patient was diagnosed with COVID-19. Concomitant medications included lithium carbonate (MANUFACTURER UNKNOWN), quetiapine fumarate (SEROQUEL), lisdexamfetamine mesilate (VYVANSE) and hydroxyzine (MANUFACTURER UNKNOWN); all for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to vaccination. On 19Apr2021 at 17:30, day 1, the patient experienced moderate fatigue, frequent diarrhea and mild nausea. On 20Apr2021, day 2-4, the patient experienced sneezing constantly, dry but runny eyes and nose, mild cough, extremely fatigued, rash on hands, face, and chest, frequent diarrhea, 7- 10 episodes of vomiting, severe nausea and no soreness. On 23Apr2021,day 5, the patient had abdominal cramping, moderate runny nose and eyes, sneezing, moderate nausea and frequent diarrhea. On 24Apr2021, day 6, the period started 5 days early and experienced extremely fatigued, no sneezing, mild runny eyes and nose, no nausea and moderate diarrhea. The patient did not have any swelling or soreness and reported that vaccine was painless. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events moderate fatigue, frequent diarrhea, mild nausea, sneezing constantly, dry but runny eyes and nose, mild cough, extremely fatigued, rash on hands, face, and chest, 7- 10 episodes of vomiting, severe nausea, abdominal cramping, moderate runny nose and eyes, moderate nausea and period started 5 days early was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Period starts 5 days early; Abdominal cramping; Sneezing constantly; Dry but runny nose/ moderate runny nose/ mild runny nose; Mild cough; Dry but runny eyes/ moderate runny eyes/ mild runny eyes; Rash on hands, face, and chest; 7-10 episodes of vomiting; Moderate fatigue /extremely fatigued; Frequent diarrhea/ moderate diarrhea; Mild nausea / severe nausea /moderate nausea; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 18Apr2021 at 14:00 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history includes bipolar 1, attention deficit-hyperactivity disorder (ADHD), anxiety, post-traumatic stress disorder (PTSD), arthritis, asthma, psoriasis, COVID-19, allergic to cats and certain food colorings if ingested. Prior to vaccination, the patient was diagnosed with COVID-19. Concomitant medications included lithium carbonate (MANUFACTURER UNKNOWN), quetiapine fumarate (SEROQUEL), lisdexamfetamine mesilate (VYVANSE) and hydroxyzine (MANUFACTURER UNKNOWN); all for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to vaccination. On 19Apr2021 at 17:30, day 1, the patient experienced moderate fatigue, frequent diarrhea and mild nausea. On 20Apr2021, day 2-4, the patient experienced sneezing constantly, dry but runny eyes and nose, mild cough, extremely fatigued, rash on hands, face, and chest, frequent diarrhea, 7- 10 episodes of vomiting, severe nausea and no soreness. On 23Apr2021,day 5, the patient had abdominal cramping, moderate runny nose and eyes, sneezing, moderate nausea and frequent diarrhea. On 24Apr2021, day 6, the period started 5 days early and experienced extremely fatigued, no sneezing, mild runny eyes and nose, no nausea and moderate diarrhea. The patient did not have any swelling or soreness and reported that vaccine was painless. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events moderate fatigue, frequent diarrhea, mild nausea, sneezing constantly, dry but runny eyes and nose, mild cough, extremely fatigued, rash on hands, face, and chest, 7- 10 episodes of vomiting, severe nausea, abdominal cramping, moderate runny nose and eyes, moderate nausea and period started 5 days early was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Severe Arm soreness; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0172) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Apr2021 at 12:00 the patient experienced severe arm soreness. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event severe arm soreness was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Swollen tongue
Clinical narrative: Tongue started swelling; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the right arm on 19Apr2021 (at the age of 62-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included unspecified blood pressure meds (MANUFACTURE UNKNOWN) for unspecified indications, from an unknown date and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On 19Apr2021, the patient experienced tongue started swelling and white welms occurred 2 hours after vaccine was administered. Since the vaccination, it was unknown if the patient was tested for COVID-19. Therapeutic measures were taken as a result of event tongue started swelling and white welms which included diphenhydramine hydrochloride (BENADRYL) from on unknown date. The clinical outcome of the events Tongue started swelling and white welms were recovering at the time of report.   No follow-up attempts are possible. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Heavy menstrual bleeding, Menstruation irregular
Clinical narrative: Menstruation began the next day after the vaccine was administered. It was 2 weeks early.; Period was extremely heavy/It lasted for 14 days; Headache; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: BP7533) via an unspecified route of administration in the left arm on 03Apr2021 at 10:00 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. Medical history included thyroid cancer on 2006 and unknown if ongoing. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medication included birth control pills (MANUFACTURER UNKNOWN) taken for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Apr2021 at 10:00, the next day after the vaccination, the patient experienced menstruation which was 2 weeks early. Her cycle was regulated by birth control pills so it was always regular where vaccine started her period the way the placebo pill does on her birth control pills. Her period was extremely heavy and never had heavy bleeding prior to the vaccine. It lasted for 14 days whereas her regular period was light and lasts 3-4 days. She had a headache for 7 days and 7th day her headache was so extreme that she was about to go to the Emergency Room but she was worried about the costs of the ER so she didn't go. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event menstruation began the next day after the vaccine was administered and 2 weeks early and extremely heavy period was recovered on 18Apr2021. The clinical outcome of the event headache was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Influenza like illness, Pain in extremity, Pyrexia
Clinical narrative: Flu like symptoms the day after; Very sore arm; Joint aches; Uncontrollable shaking for a couplehours; Fever; Chills; This is a spontaneous report from a non-contactable consumer, the patient. A 29-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 23Apr2021 at 09:00 (at the age of 29-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included unspecified over the counter allergy medicine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 02Apr2021 at 08:30 (at the age of 29-year-old) as a single dose for COVID-19 immunisation. On 23Apr2021 at 20:00, the patient experienced very sore arm, joint aches, uncontrollable shaking for a couple of hours, fever and chills. On 24Apr2021 (reported as the day after), the patient experienced flu like symptoms. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events very sore arm, joint aches, uncontrollable shaking for a couple of hours, fever, chills and flu like symptoms was resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 29.0
Sex: M
Vaccine: COVID19
Symptoms: Tremor
Clinical narrative: Flu like symptoms the day after; Very sore arm; Joint aches; Uncontrollable shaking for a couplehours; Fever; Chills; This is a spontaneous report from a non-contactable consumer, the patient. A 29-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 23Apr2021 at 09:00 (at the age of 29-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included unspecified over the counter allergy medicine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 02Apr2021 at 08:30 (at the age of 29-year-old) as a single dose for COVID-19 immunisation. On 23Apr2021 at 20:00, the patient experienced very sore arm, joint aches, uncontrollable shaking for a couple of hours, fever and chills. On 24Apr2021 (reported as the day after), the patient experienced flu like symptoms. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events very sore arm, joint aches, uncontrollable shaking for a couple of hours, fever, chills and flu like symptoms was resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Lymph node pain, Lymphadenopathy
Clinical narrative: Swollen and painful lymph node near collarbone; Swollen and painful lymph node near collarbone; Achy joints; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the right arm on 22Apr2021 at 14:45 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included seasonal allergies and sports induced asthma. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received unspecified concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the right arm on 01Apr2021 at 15:30 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Apr2021 at 07:30, the patient experienced swollen and painful lymph node near collarbone and achy joints. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swollen and painful lymph node near collarbone and achy joints were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Condition aggravated, Pain in extremity, Peripheral swelling
Clinical narrative: pain and swelling in her fingers and toes; pain and swelling in her fingers and toes; having a bad flare a week after getting first covid vaccine; This is a spontaneous report from a contactable other hcp (clinician). A 53-year-old female patient received bnt162b2 (BNT162B2 formulation; Solution for injection), dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as DOSE 1, SINGLE for covid-19 immunisation. The patient received tofacitinib citrate (XELJANZ XR Prolonged-release tablet), oral from 09Jan2020 (Batch/Lot number was not reported) and ongoing, at 11 mg, daily for rheumatoid arthritis. Medical history included rheumatoid arthritis from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. The patient experienced pain and swelling in her fingers and toes and bad flare a week after getting first covid vaccine on an unknown date of Apr2021. Xeljanz was not held during this time. It was reported that MD was aware. The patient prescribed prednisone to help relieve the swelling and pain. The patient would wait a week or two before getting the second vaccine. Therapeutic measures were taken as a result of pain and swelling in her fingers and toes. The action taken in response to the events for tofacitinib citrate was dose not changed. The outcome of event was unknown.  No follow-up attempts are needed. Information about lot/batch number cannot be obtained.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Hypersomnia, Pruritus, Rash papular
Clinical narrative: Extreme fatigue on day 6-7; Slept 14 hours; Itchy raised rash on chest and arms starting approximately 4-5 days after vaccine; Extreme itching, it woke me up in the middle of the night; This is a spontaneous report from a contactable nurse, the patient. A 55-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration on 17Apr2021 at 14:30 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history included history of cancer. The patient had known allergy to radiography dye. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included resveratrol (MANUFACTURER UNKNOWN), NMN and berberine (MANUFACTURER UNKNOWN); all taken for unknown indications from an unknown date and unknown if ongoing. On 21Apr2021 at 03:00, approximately 4-5 days after vaccine, the patient experienced itchy raised rash on chest and arms. The patient had extreme itching, it woke her up in the middle of the night. On 23Apr2021, 6-7 day after vaccine, the patient experienced extreme fatigue and slept 14 hours. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events itchy raised rash on chest and arms starting approximately 4-5 days after vaccine, extreme itching, it woke her up in the middle of the night, extreme fatigue on day 6-7 and slept 14 hours were not recovered at the time of report.  No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Acne, Rash papular
Clinical narrative: Broke out with a bumpy rash all over chest and face (cheeks, chin area).; Almost looks like clogged pores or acne but was not there prior.; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 19Apr2021 at 11:30 as a single dose for COVID-19 immunisation. Medical history included hypothyroidism and mild autoimmune. The patient had a history of allergy to peanuts, pine nuts, avocado, penicillin and sulfa drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), ammonium chloride, diphenhydramine hydrochloride, menthol, sodium citrate (BENADRYL) and lifitegrast (XIIDRA) eyedrops; all from unknown date for unknown indication and unknown if ongoing. The patient previously took cefaclor (CECLOR) and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 25Mar2021 at 11:00 as a single dose for COVID-19 immunisation. On 21Apr2021 at 21:00, the patient experienced broke out with a bumpy rash all over my chest and face (cheeks, chin area) which was almost looks like clogged pores or acne but was not there prior. It was slowly subsiding but still present five days later. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as result of events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events broke out with a bumpy rash all over chest and face (cheeks, chin area) and almost looks like clogged pores or acne but was not there prior was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Pain, Paraesthesia, Pyrexia, Vaccination site erythema
Clinical narrative: Redness in injection site; Itchiness in injection site; Minor swelling in injection site; Severe body aches while on antiinflammatorymeds; fever of 101 while on meds; Skin hurt like needles stabbing; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot number: Er8735) via an unspecified route of administration in the left arm on 19Apr2021 at 09:15 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history included allergic to walnuts and cough medications. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included cetirizine hydrochloride (ZYRTEC) and budesonide (NASOCORT); both for an unknown indication from an unknown date and unknown if ongoing. The patient previously received some antifungal medications, miconazole nitrate (MONISTAT) and lidocaine (VAGISIL) for an unknown indication from an unknown date and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Er8732) via an unspecified route of administration in the left arm on 29Mar2021 at 09:15 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. On 19Apr2021, the patient experienced severe body aches while on anti-inflammatory medicines, fever of 101 while on medicines, skin hurt like needles stabbing all started about 3 hours after injection and lasted for about 36 hours. On 23Apr2021, 4 days after the injection, the patient experienced redness, itchiness and minor swelling in injection site. Swelling and redness lasted for about 24 hours. On 19Apr2021, the patient underwent lab tests and procedures which included body temperature test and the result was found to be 101 (unspecified units). The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Therapeutic measures taken as a result of the reported events severe body aches included treatment with anti-inflammatory medicines and the treatment for fever included unspecified medicines. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe body aches, fever, skin hurt like needles stabbing were recovered on an unknown date in Apr2021 which lasted for about 36 hours, while the events minor swelling and redness in injection site were recovered on an unknown date in Apr2021 which lasted about 24 hours and the event itchiness at the injection site was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pruritus, Vaccination site swelling
Clinical narrative: Redness in injection site; Itchiness in injection site; Minor swelling in injection site; Severe body aches while on antiinflammatorymeds; fever of 101 while on meds; Skin hurt like needles stabbing; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot number: Er8735) via an unspecified route of administration in the left arm on 19Apr2021 at 09:15 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history included allergic to walnuts and cough medications. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included cetirizine hydrochloride (ZYRTEC) and budesonide (NASOCORT); both for an unknown indication from an unknown date and unknown if ongoing. The patient previously received some antifungal medications, miconazole nitrate (MONISTAT) and lidocaine (VAGISIL) for an unknown indication from an unknown date and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Er8732) via an unspecified route of administration in the left arm on 29Mar2021 at 09:15 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. On 19Apr2021, the patient experienced severe body aches while on anti-inflammatory medicines, fever of 101 while on medicines, skin hurt like needles stabbing all started about 3 hours after injection and lasted for about 36 hours. On 23Apr2021, 4 days after the injection, the patient experienced redness, itchiness and minor swelling in injection site. Swelling and redness lasted for about 24 hours. On 19Apr2021, the patient underwent lab tests and procedures which included body temperature test and the result was found to be 101 (unspecified units). The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Therapeutic measures taken as a result of the reported events severe body aches included treatment with anti-inflammatory medicines and the treatment for fever included unspecified medicines. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe body aches, fever, skin hurt like needles stabbing were recovered on an unknown date in Apr2021 which lasted for about 36 hours, while the events minor swelling and redness in injection site were recovered on an unknown date in Apr2021 which lasted about 24 hours and the event itchiness at the injection site was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Peripheral swelling
Clinical narrative: Hurting joints in my knees and especially in my hands when i grip things; Hands feel swollen but don't look swollen; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 14Apr2021 at 12:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included minor anxiety. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included fluoxetine (MANUFACTURER UNKNOWN); taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 17Mar2021 at 12:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. On 17Apr2021 at 12:00, the patient had hurting joints in his knees and especially in his hands when he grips things. Hands felt swollen but did not look swollen. Onset was within a few days of the second dose and seemed to be getting worse instead of better. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events hurting joints in knees and especially in hands when he grips things and hands felt swollen but did not look swollen was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.